195 related articles for article (PubMed ID: 38300310)
21. Screening BRCA1 and BRCA2 unclassified variants for splicing mutations using reverse transcription PCR on patient RNA and an ex vivo assay based on a splicing reporter minigene.
Bonnet C; Krieger S; Vezain M; Rousselin A; Tournier I; Martins A; Berthet P; Chevrier A; Dugast C; Layet V; Rossi A; Lidereau R; Frébourg T; Hardouin A; Tosi M
J Med Genet; 2008 Jul; 45(7):438-46. PubMed ID: 18424508
[TBL] [Abstract][Full Text] [Related]
22. Identification of Eight Spliceogenic Variants in BRCA2 Exon 16 by Minigene Assays.
Fraile-Bethencourt E; Valenzuela-Palomo A; Díez-Gómez B; Acedo A; Velasco EA
Front Genet; 2018; 9():188. PubMed ID: 29881398
[TBL] [Abstract][Full Text] [Related]
23. Classification of BRCA2 Variants of Uncertain Significance (VUS) Using an ACMG/AMP Model Incorporating a Homology-Directed Repair (HDR) Functional Assay.
Hu C; Susswein LR; Roberts ME; Yang H; Marshall ML; Hiraki S; Berkofsky-Fessler W; Gupta S; Shen W; Dunn CA; Huang H; Na J; Domchek SM; Yadav S; Monteiro ANA; Polley EC; Hart SN; Hruska KS; Couch FJ
Clin Cancer Res; 2022 Sep; 28(17):3742-3751. PubMed ID: 35736817
[TBL] [Abstract][Full Text] [Related]
24. Functional pre-therapeutic evaluation by genome editing of variants of uncertain significance of essential tumor suppressor genes.
Billaud A; Chevalier LM; Augereau P; Frenel JS; Passot C; Campone M; Morel A
Genome Med; 2021 Nov; 13(1):174. PubMed ID: 34749799
[TBL] [Abstract][Full Text] [Related]
25. Impact of proactive high-throughput functional assay data on BRCA1 variant interpretation in 3684 patients with breast or ovarian cancer.
Kim HK; Lee EJ; Lee YJ; Kim J; Kim Y; Kim K; Lee SW; Chang S; Lee YJ; Lee JW; Lee W; Chun S; Son BH; Jung KH; Kim YM; Min WK; Ahn SH
J Hum Genet; 2020 Mar; 65(3):209-220. PubMed ID: 31907386
[TBL] [Abstract][Full Text] [Related]
26. Landscape of germline
Ferreyra Y; Rosas G; Cock-Rada AM; Araujo J; Bravo L; Doimi F; Casas J; Clavo MLÁ; Pinto JA; Belmar-López C
Front Oncol; 2023; 13():1227864. PubMed ID: 37664050
[TBL] [Abstract][Full Text] [Related]
27. Exon splicing analysis of intronic variants in multigene cancer panel testing for hereditary breast/ovarian cancer.
Ryu JS; Lee HY; Cho EH; Yoon KA; Kim MK; Joo J; Lee ES; Kang HS; Lee S; Lee DO; Lim MC; Kong SY
Cancer Sci; 2020 Oct; 111(10):3912-3925. PubMed ID: 32761968
[TBL] [Abstract][Full Text] [Related]
28. Incorporation of semi-quantitative analysis of splicing alterations for the clinical interpretation of variants in BRCA1 and BRCA2 genes.
Montalban G; Bonache S; Moles-Fernández A; Gadea N; Tenés A; Torres-Esquius S; Carrasco E; Balmaña J; Diez O; Gutiérrez-Enríquez S
Hum Mutat; 2019 Dec; 40(12):2296-2317. PubMed ID: 31343793
[TBL] [Abstract][Full Text] [Related]
29. RNA analysis of eight BRCA1 and BRCA2 unclassified variants identified in breast/ovarian cancer families from Spain.
Campos B; Díez O; Domènech M; Baena M; Balmaña J; Sanz J; Ramírez A; Alonso C; Baiget M
Hum Mutat; 2003 Oct; 22(4):337. PubMed ID: 12955719
[TBL] [Abstract][Full Text] [Related]
30. Characterization of BRCA1 and BRCA2 variants found in a Norwegian breast or ovarian cancer cohort.
Jarhelle E; Riise Stensland HM; Mæhle L; Van Ghelue M
Fam Cancer; 2017 Jan; 16(1):1-16. PubMed ID: 27495310
[TBL] [Abstract][Full Text] [Related]
31. Germline mutations in BRCA1 and BRCA2 in epithelial ovarian cancer patients in Brazil.
Maistro S; Teixeira N; Encinas G; Katayama ML; Niewiadonski VD; Cabral LG; Ribeiro RM; Gaburo Junior N; de Gouvêa AC; Carraro DM; Sabino EC; Diz MD; Chammas R; de Bock GH; Folgueira MA
BMC Cancer; 2016 Dec; 16(1):934. PubMed ID: 27914478
[TBL] [Abstract][Full Text] [Related]
32. Clinical implications of VUS reclassification in a single-centre series from application of ACMG/AMP classification rules specified for
Innella G; Ferrari S; Miccoli S; Luppi E; Fortuno C; Parsons MT; Spurdle AB; Turchetti D
J Med Genet; 2024 Apr; 61(5):483-489. PubMed ID: 38160042
[TBL] [Abstract][Full Text] [Related]
33. Spectrum and characterisation of BRCA1 and BRCA2 deleterious mutations in high-risk Czech patients with breast and/or ovarian cancer.
Machackova E; Foretova L; Lukesova M; Vasickova P; Navratilova M; Coene I; Pavlu H; Kosinova V; Kuklova J; Claes K
BMC Cancer; 2008 May; 8():140. PubMed ID: 18489799
[TBL] [Abstract][Full Text] [Related]
34. BRCA1/2 sequence variants of uncertain significance: a primer for providers to assist in discussions and in medical management.
Lindor NM; Goldgar DE; Tavtigian SV; Plon SE; Couch FJ
Oncologist; 2013; 18(5):518-24. PubMed ID: 23615697
[TBL] [Abstract][Full Text] [Related]
35. Ovarian cancer pathology characteristics as predictors of variant pathogenicity in BRCA1 and BRCA2.
O'Mahony DG; Ramus SJ; Southey MC; Meagher NS; Hadjisavvas A; John EM; Hamann U; Imyanitov EN; Andrulis IL; Sharma P; Daly MB; Hake CR; Weitzel JN; Jakubowska A; Godwin AK; Arason A; Bane A; Simard J; Soucy P; Caligo MA; Mai PL; Claes KBM; Teixeira MR; Chung WK; Lazaro C; Hulick PJ; Toland AE; Pedersen IS; ; Neuhausen SL; Vega A; de la Hoya M; Nevanlinna H; Dhawan M; Zampiga V; Danesi R; Varesco L; Gismondi V; Vellone VG; James PA; Janavicius R; Nikitina-Zake L; Nielsen FC; van Overeem Hansen T; Pejovic T; Borg A; Rantala J; Offit K; Montagna M; Nathanson KL; Domchek SM; Osorio A; García MJ; Karlan BY; ; De Fazio A; Bowtell D; ; McGuffog L; Leslie G; Parsons MT; Dörk T; Speith LM; Dos Santos ES; da Costa AABA; Radice P; Peterlongo P; Papi L; Engel C; Hahnen E; Schmutzler RK; Wappenschmidt B; Easton DF; Tischkowitz M; Singer CF; Tan YY; Whittemore AS; Sieh W; Brenton JD; Yannoukakos D; Fostira F; Konstantopoulou I; Soukupova J; Vocka M; ; Chenevix-Trench G; Pharoah PDP; Antoniou AC; Goldgar DE; Spurdle AB; Michailidou K; ;
Br J Cancer; 2023 Jun; 128(12):2283-2294. PubMed ID: 37076566
[TBL] [Abstract][Full Text] [Related]
36. In silico, in vitro and case-control analyses as an effective combination for analyzing BRCA1 and BRCA2 unclassified variants in a population-based sample.
Rodríguez-Balada M; Roig B; Martorell L; Melé M; Salvat M; Vilella E; Borràs J; Gumà J
Cancer Genet; 2016 Nov; 209(11):487-492. PubMed ID: 27886673
[TBL] [Abstract][Full Text] [Related]
37. Retrospective reinterpretation and reclassification of BRCA1/2 variants from Chinese population.
Li D; Shi Y; Li A; Cao D; Su H; Yang H; Zhi Q; Yang Y; Lan Z; Zhou T; You X; Hu G
Breast Cancer; 2020 Nov; 27(6):1158-1167. PubMed ID: 32566972
[TBL] [Abstract][Full Text] [Related]
38. Changes in classification of genetic variants in BRCA1 and BRCA2.
Kast K; Wimberger P; Arnold N
Arch Gynecol Obstet; 2018 Feb; 297(2):279-280. PubMed ID: 29302806
[TBL] [Abstract][Full Text] [Related]
39. Germline variants profiling of BRCA1 and BRCA2 in Chinese Hakka breast and ovarian cancer patients.
Zhang Y; Wu H; Yu Z; Li L; Zhang J; Liang X; Huang Q
BMC Cancer; 2022 Aug; 22(1):842. PubMed ID: 35918668
[TBL] [Abstract][Full Text] [Related]
40. Clinical and molecular characterization of the BRCA2 p.Asn3124Ile variant reveals substantial evidence for pathogenic significance.
Surowy HM; Sutter C; Mittnacht M; Klaes R; Schaefer D; Evers C; Burgemeister AL; Goehringer C; Dikow N; Heil J; Golatta M; Schott S; Schneeweiss A; Bugert P; Sohn C; Bartram CR; Burwinkel B
Breast Cancer Res Treat; 2014 Jun; 145(2):451-60. PubMed ID: 24728577
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
